Does NIVOLUMAB Cause Immune-mediated thyroiditis? 156 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 156 reports of Immune-mediated thyroiditis have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.2% of all adverse event reports for NIVOLUMAB.
156
Reports of Immune-mediated thyroiditis with NIVOLUMAB
0.2%
of all NIVOLUMAB reports
3
Deaths
76
Hospitalizations
How Dangerous Is Immune-mediated thyroiditis From NIVOLUMAB?
Of the 156 reports, 3 (1.9%) resulted in death, 76 (48.7%) required hospitalization, and 15 (9.6%) were considered life-threatening.
Is Immune-mediated thyroiditis Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for NIVOLUMAB. However, 156 reports have been filed with the FAERS database.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Immune-mediated thyroiditis?
PEMBROLIZUMAB (189)
IPILIMUMAB (109)
CARBOPLATIN (50)
PACLITAXEL (34)
LENVATINIB (29)
CYCLOPHOSPHAMIDE (13)
PEMETREXED (11)
ACETAMINOPHEN (10)
ASPIRIN (10)
CLOPIDOGREL BISULFATE (10)
Which NIVOLUMAB Alternatives Have Lower Immune-mediated thyroiditis Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE